Open AccessS155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE
Author(s) -
Rea D.,
Hochhaus A.,
Mauro M. J.,
Minami Y.,
Lomaia E.,
Voloshin S.,
Turkina A.,
Kim D.W.,
Apperley J. F.,
Cortes J. E.,
Abdo A.,
Fogliatto L. M.,
Kim D. D. H,
Coutre P.,
Saussele S.,
Annunziata M.,
Hughes T. P.,
Chaudhri N.,
Chee L.,
GarcíaGutiérrez V.,
Sasaki K.,
Kapoor S.,
Allepuz A.,
Quenet S.,
Bédoucha V.,
Boquimpani C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843512.62237.dc
Subject(s) - medicine , bosutinib , discontinuation , tolerability , adverse effect , imatinib , myeloid leukemia , nilotinib , gastroenterology